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Blood Pressure Lowering With Nilvadipine in Patients With
Mild-to-Moderate Alzheimer Disease Does Not Increase the
Prevalence of Orthostatic Hypotension
Rianne A. A. de Heus, MSc; Rogier Donders, PhD; Angelina M. M. Santoso, MSc; Marcel G. M. Olde Rikkert, MD, PhD; Brian A. Lawlor, MD;
Jurgen A. H. R. Claassen, MD, PhD; for the Nilvad Study Group*
Background-—Hypertension is common among patients with Alzheimer disease. Because this group has been excluded from
hypertension trials, evidence regarding safety of treatment is lacking. This secondary analysis of a randomized controlled trial
assessed whether antihypertensive treatment increases the prevalence of orthostatic hypotension (OH) in patients with Alzheimer
disease.
Methods and Results-—Four hundred seventy-seven patients with mild-to-moderate Alzheimer disease were randomized to the
calcium-channel blocker nilvadipine 8 mg/day or placebo for 78 weeks. Presence of OH (blood pressure drop ≥20/≥10 mm Hg
after 1 minute of standing) and OH-related adverse events (dizziness, syncope, falls, and fractures) was determined at 7 follow-up
visits. Mean age of the study population was 72.28.2 years and mean Mini-Mental State Examination score was 20.43.8.
Baseline blood pressure was 137.814.0/77.08.6 mm Hg. Grade I hypertension was present in 53.4% (n=255). After 13 weeks,
blood pressure had fallen by 7.8/3.9 mm Hg for nilvadipine and by 0.4/0.8 mm Hg for placebo (P<0.001). Across the 78-
week intervention period, there was no difference between groups in the proportion of patients with OH at a study visit (odds ratio
[95% CI]=1.1 [0.8–1.5], P=0.62), nor in the proportion of visits where a patient met criteria for OH, corrected for number of visits
(7.713.8% versus 7.311.6%). OH-related adverse events were not more often reported in the intervention group compared with
placebo. Results were similar for those with baseline hypertension.
Conclusions-—This study suggests that initiation of a low dose of antihypertensive treatment does not signiﬁcantly increase the
risk of OH in patients with mild-to-moderate Alzheimer disease.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT02017340. ( J Am Heart Assoc. 2019;8:
e011938. DOI: 10.1161/JAHA.119.011938)
Key Words: adverse drug event • Alzheimer disease • antihypertensive agent • calcium channel blocker • orthostatic
hypotension • randomized controlled trial
W ith an estimated prevalence of 45%, hypertension is acommon comorbidity among patients with Alzheimer
disease (AD).1 Despite this high prevalence, this patient
group has not been represented in hypertension trials,
leading to uncertainty regarding the beneﬁt-to-risk ratio of
antihypertensive treatment in these patients.2 This same
discussion concerns frail, older people in general.3 In the
absence of evidence, current guidelines advise being
cautious when starting antihypertensive treatment in these
groups.4–6
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A widely voiced concern among physicians is that older
people develop orthostatic hypotension (OH) following anti-
hypertensive treatment.7 The prevalence of OH increases with
age,8 and has been associated with cognitive decline,9
possibly caused by AD pathology. OH is an independent risk
factor for future falls.10 Therefore, if antihypertensive treat-
ment increases the risk of OH, it could unintentionally lead to
increased frailty, institutionalization, or mortality,11 especially
in AD, where cerebral hypoperfusion following OH could
accelerate cognitive decline.12
Evidence about antihypertensive treatment and OH has
mainly emanated from observational studies,13–16 while
results from randomized clinical trials in healthy older people
showed that improved control of blood pressure (BP) did not
result in a larger difference between sitting and standing
BP.17,18 Whether this also holds for frail populations, such as
patients with AD, is currently unknown.
The Nilvad trial was designed to investigate the putative
anti-amyloid properties of the calcium-channel blocker nil-
vadipine in mild-to-moderate AD.19 The trial result was
negative for cognitive and functional outcomes.20 However,
nilvadipine’s antihypertensive properties are comparable to
other, more commonly used, calcium-channel blockers.21,22
Therefore, preplanned monitoring of BP throughout the study
allowed us to explore the effect of starting an antihyperten-
sive drug on the prevalence of OH in AD. Speciﬁcally, the aim
of this study was to investigate whether BP lowering with
nilvadipine increased the prevalence of OH and OH-related
clinical outcomes in patients with mild-to-moderate AD.
Methods
Because of agreements within the Nilvad consortium, the data
that support the ﬁndings of this cannot be made available to
other researchers for purposes of reproducing the results or
replicating the procedure. The corresponding author had full
access to all the data in the study and takes responsibility for
its integrity and the data analysis.
Study Design
The Nilvad trial (NCT02017340) was a randomized, double-
blind, placebo-controlled trial, conducted at 23 sites in 9
European countries. The trial was approved by institutional
review boards of each participating country, and all patients
as well as relevant caregivers gave written informed consent.
A complete description of the trial has been published
previously.19 The main outcome of the trial and any changes
made to the study protocol after trial commencement have
been reported by Lawlor et al (2018).20
Participants
Patients were recruited from 13 academic and 10 general
memory clinics. Patients were eligible if they (1) met the
criteria of the National Institute of Neurological and Commu-
nicative Disorders and Stroke-Alzheimer’s disease and
Related Disorders Association23 for the diagnosis mild-to-
moderate probable AD, (2) were aged ≥50 years, (3) scored
between 12 and 26 on the Mini-Mental State Examination,24
(4) had a caregiver available, and (5) were not using a calcium-
channel blocker, b-blocker, or a-blocker. For safety reasons,
since the trial was not designed to investigate BP lowering, BP
had to be between 100 and 159 mm Hg for systolic and
between 65 and 99 mm Hg for diastolic BP. Patients using a
cholinesterase inhibitor or memantine were eligible if they
were on a stable dose for 3 months before screening. The
main exclusion criteria were dementia resulting from other
causes and the presence of a medical condition that,
according to the physician, would preclude participation. A
detailed list of inclusion and exclusion criteria is provided in
the trial protocol.19
Intervention
The trial used a parallel-group design with a 1:1 allocation
ratio to 8 mg nilvadipine or placebo once daily. Antihyper-
tensive properties of 8 mg of nilvadipine are comparable to
5 mg of amlodipine.22 Randomization and blinding processes
have been described elsewhere.19 Brieﬂy, randomization was
stratiﬁed by study site and all study staff was blind to
randomization. Study medication was dispensed per 98
capsules at baseline and at every 13-week follow-up. Com-
pliance was monitored by collecting the used treatment packs
and leftover capsules at each visit. Postrandomization visits
occurred at weeks 6, 13, 26, 39, 52, 65, and 78.
Clinical Perspective
What Is New?
• Lowering blood pressure with a low dose of the calcium-
channel blocker nilvadipine does not increase the preva-
lence of orthostatic hypotension in patients with mild-to-
moderate Alzheimer disease.
• This ﬁnding was independent of initial blood pressure level
or frailty score.
What Are the Clinical Implications?
• This study adds to the discussion on the beneﬁt-to-risk ratio
of antihypertensive treatment in patients with Alzheimer
disease.
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Measurements
At every visit, intermittent BP was measured by qualiﬁed study
site staff after 5 minutes of rest in the sitting position, and
again after 1 and 5 minutes of standing, using a manual
sphygmomanometer. Any symptoms noted during standing
were recorded. At baseline, the Alzheimer’s Disease Assess-
ment scale25 was used to assess cognitive function, the
Disability Assessment for Dementia questionnaire26 was used
to assess functional abilities, and the Clinical Dementia Rating
scale27 was used to characterize dementia stage. For patients
who had consented to the Nilvad frailty-substudy, a baseline
frailty index was derived.28,29 This index comprised the ratio
of deﬁcits present out of 26 possible deﬁcits across multiple
domains, resulting in a score between 0 and 1 (see Table S1
for a detailed description). We classiﬁed patients as ﬁt (index
≤0.10), less ﬁt (0.10<index≤0.21), or frail (index>0.21)
analogous with the SPRINT (Systolic Blood Pressure Interven-
tion Trial) criteria.30 Adverse events and concomitant medi-
cation use were assessed using structured interviews with
patient and caregiver at every visit. Concomitant medication
was coded according to the Anatomical Therapeutic Chemical
classiﬁcation system. The study allowed initiation or termina-
tion of other antihypertensive medication in case patients
developed high or low BP during the study.
Outcomes
We constructed 3 dichotomous outcomes of OH. Classic OH:
a drop of ≥20 mm Hg in systolic blood pressure (SBP) or
≥10 mm Hg in diastolic blood pressure (DBP) after 1 minute
of standing compared with sitting BP (consensus criteria);31
sit-to-stand OH: a drop of ≥15 mm Hg in SBP or ≥7 mm Hg in
DBP after 1 minute of standing;32 and symptomatic OH: the
presence of symptoms upon standing, irrespective of the drop
in BP. This latter category (symptoms suggestive of OH) was
included to reduce the risk of missing OH because of false-
negative intermittent BP measurements. In addition, we
examined the change in SBP from sitting to standing on a
continuous scale (DSBP, in mm Hg and %) and the presence
of classic OH after 5 minutes of standing, referred to as
delayed OH.13 Clinical outcomes were reported adverse
events of fractures, falls, syncope, and dizziness.
Statistical Analyses
The effect of treatment on OH was examined in 2 ways. First,
multivariable logistic regression examined the effect of treat-
ment on the proportion of OH at follow-up, with ﬁxed effects for
treatment, baselineDSBP (mean-centered), time and time*treat-
ment interaction, and random intercepts for patient and study
center, to address correlations resulting from repeated
measures and center-speciﬁc effects. In case time*treatment
interaction was not signiﬁcant, it was dropped from the model.
Second, we examined the effect of treatment on the number of
follow-up visits in which a patient met criteria for OH, using the
total number of visits for that patient as the denominator.
Descriptive summaries of these results are presented.
In addition, linear regression was applied to examine the
effect of treatment on DSBP, with ﬁxed effects for treatment,
baseline DSBP, time and time*treatment interaction, and
random intercepts for patient and study center. The effect of
treatment on the presence of reported clinical outcomes
during follow-up was evaluated with logistic regression.
To test for any potential moderating effects, the following
baseline variables and the interaction term for these variables
with treatment were added as predictors in the analyses
described above: BP status (high: ≥140/90 mm Hg, normal:
130 to 139/70 to 89 mm Hg or low: <130/70 mm Hg BP at
baseline), Mini-Mental State Examination score, age, frailty
index, diabetes mellitus, use of additional antihypertensive
medication parallel to the intervention, use of cholinesterase
inhibitors, and use of antidepressants.
Analyses were performed on the per protocol population,
including only measurements of patients with ≥80% treatment
compliance in the 3-month window before that particular
measurement. A complete cases analysis (patients included in
all 7 follow-up visits) was performed as well. Missing values
were not imputed. Two-sided testing and an alpha level of
0.05 were used. Since the analyses were performed post hoc,
P values should be interpreted with caution and 95% CI of the
outcomes that are reported were appropriate. Analyses were
performed with SPSS Statistics software version 22.0 and
R.33
Results
Characteristics
The Nilvad trial was conducted between May 2013 and
November 2016. Among 511 randomized patients, 477
(93.3%) were included in the current per protocol analysis
(Figure 1). The proportion of patientswho completed all 7 follow-
up visits was 68.3% for nilvadipine and 70.5% for placebo
(P=0.61). Table 1 shows the baseline demographics and clinical
characteristics. Characteristics were the same for the complete
cases (Table S2). Reasons to be excluded from the per protocol
analysis are detailed in Table S3. The proportion of patients who
continuously used an antihypertensive agent parallel to the
intervention was 25.4% for nilvadipine and 31.6% for placebo
(P=0.13). In thenilvadipine group, 5.0%startedwith anadditional
antihypertensive drug, whereas 7.9% stopped one. In the
placebo group this was 9.3% versus 6.8%, respectively.
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Changes in Sitting Blood Pressure
Figure 2 shows the mean sitting SBP and DBP throughout the
study. At baseline, sitting SBP and DBP were 138.3
13.7 mm Hg (meanSD) and 76.78.7 mm Hg for nilvadip-
ine and 137.214.2 mm Hg and 77.28.6 mm Hg for
placebo. The proportion of patients with baseline hyperten-
sion (BP≥140/90 mm Hg) was 57.1% for nilvadipine and
49.8% for placebo. After 13 weeks of treatment, sitting SBP
and DBP had dropped by 7.814.0 and 3.98.7 mm Hg for
nilvadipine and with 0.414.1 and 0.89.1 mm Hg for
placebo (P<0.001 for SBP and DBP). This effect did not differ
between those with high, normal, and low BP at baseline
(Figure S1), nor between those who did, versus did not, use
additional antihypertensive drugs parallel to the intervention
(Figure S2). Similar results were observed for the complete
cases (Figure S2).
Orthostatic Hypotension and Clinical Outcomes
Of 477 patients, 32.9% (n=79) in the nilvadipine group and
34.6% (n=82) in the placebo group met the criteria for classic
OH at least once during follow-up. These proportions were
52.7% and 47.3% for sit-stand OH, 8.3% and 11.4% for
symptomatic OH, and 38.3% and 32.9% for delayed OH, in the
nilvadipine and placebo group, respectively. None of the OH
outcomes had a signiﬁcant time*treatment interaction (clas-
sic OH: P=0.47, sit-stand OH: P=0.78, symptomatic OH:
P=0.23, delayed OH: P=0.52), and therefore this term was
dropped from the models.
Across the 78-week follow-up, there was no statistically
signiﬁcant difference between nilvadipine and placebo in the
proportion of patients at a study visit meeting the criteria for
classic OH (odds ratio [OR]=1.1 [0.8–1.5], P=0.62), sit-stand
OH (OR=1.2 [0.9–1.5], P=0.15), symptomatic OH (OR=0.8
[0.3–2.3], P=0.55), or delayed OH (OR=1.2 [0.9–1.6], P=0.26)
(Figure 3). In addition, there was no clinically relevant effect
of nilvadipine on DSBP upon standing (in mm Hg: b=0.8
[1.7 to 0.2], P=0.13, in %: b=0.6 [1.3 to 0.2], P=0.12,
see Figure 4). Similar results were observed for complete
cases (Table S4).
The proportion of visits where a patient met criteria for OH
did not differ between the groups. For nilvadipine and
placebo, respectively, these proportions were: 7.713.8%
and 7.311.6% for classic OH, 14.818.7% and 12.215.5%
for sit-stand OH, 1.86.6% and 2.48.0% for symptomatic
OH, and 8.514.3% and 7.312.3% for delayed OH.
There were no differences between the groups in the
prevalence of OH-related relevant clinical outcomes of
fractures, falls, syncope, or dizziness (Figure 5).
Figure 1. Flow of participants. *Patients who discontinued the intervention before attending the ﬁrst follow-up visit at week 6. †Patients who
were not compliant with the study medication (compliance <80%) during any of the 3-month windows preceding a follow-up visit. ‡One patient
deceased before the ﬁrst follow-up visit at week 6 occurred. BP indicates blood pressure; MMSE, Mini-Mental State Examination score.
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Table 1. Patient Demographics and Baseline Characteristics
Characteristics Placebo (n=237) Nilvadipine (n=240)
Women, no. (%) 138 (58.2) 156 (65.0)
Age, mean (SD), y 72.0 (7.9) 72.4 (8.6)
Aged ≥75 y, no. (%) 93 (39.2) 112 (46.7)
Time since diagnosis of AD, median (IQR), y 0.9 (0.4–2.3) 1.3 (0.5–2.4)
Mini-Mental State Examination score, mean (SD) 20.5 (3.9) 20.3 (3.8)
AD Assessment Scale—cognitive subscale, mean (SD) 34.6 (10.8) 34.5 (10.5)
Clinical Dementia Rating—sum of boxes, mean (SD) 5.2 (2.7) 5.4 (2.8)
Frailty index, median (IQR)* 0.17 (0.10–0.27) 0.18 (0.11–0.26)
Fit (index≤ 0.10), no. (%) 56 (25.6) 49 (22.3)
Less fit (0.10<index≤0.21), no. (%) 90 (41.1) 86 (39.1)
Frail (index>0.21), no. (%) 73 (33.3) 85 (38.6)
Body mass index, mean (SD), kg/m2 25.9 (4.4) 25.3 (4.0)
Sitting systolic blood pressure, mean (SD), mm Hg 137.2 (14.2) 138.3 (13.7)
Sitting diastolic blood pressure, mean (SD), mm Hg 77.2 (8.6) 76.7 (8.7)
High blood pressure, no. (%) 118 (49.8) 137 (57.1)
Normal blood pressure, no. (%) 93 (39.2) 76 (31.7)
Low blood pressure, no. (%) 26 (11.0) 27 (11.3)
Resting heart rate, mean (SD), beats per min 70.1 (10.3) 70.7 (10.3)
Classic orthostatic hypotension, no. (%) 22 (9.3) 17 (7.1)
Sit-to-stand orthostatic hypotension, no. (%) 33 (13.9) 38 (15.8)
Symptomatic orthostatic hypotension, no. (%) 3 (1.3) 10 (4.2)
Delayed orthostatic hypotension, no. (%) 20 (8.4) 14 (5.8)
D Systolic blood pressure, mean (SD), mm Hg 0.3 (10.2) 1.8 (9.6)
D Systolic blood pressure, mean (SD), % 0.0 (7.3) 1.1 (7.0)
Use of medication at study enrollment, no. (%):
At least 1 antihypertensive medication 90 (38.0) 80 (33.3)
≥2 antihypertensive medications 11 (4.6) 8 (3.3)
Angiotensin II receptor blocker 40 (16.9) 33 (13.8)
Angiotensin-converting-enzyme inhibitor 46 (19.4) 38 (15.8)
Diuretic 13 (5.5) 18 (7.5)
Cholinesterase inhibitors 212 (89.5) 210 (87.5)
Memantine 62 (26.2) 64 (26.7)
Antidepressants 83 (35.0) 89 (37.1)
Benzodiazepines 12 (5.1) 7 (2.9)
Antipsychotics 11 (4.6) 11 (4.6)
Statins 79 (33.3) 84 (35.0)
Antithrombotics 58 (24.5) 61 (25.4)
History of cardiovascular disease, no. (%) 19 (8.0) 19 (7.9)
Diabetes mellitus, no. (%) 8 (3.4) 28 (11.7)
High blood pressure: ≥140/90 mm Hg; normal blood pressure: 130 to 139/70 to 89 mm Hg; low blood pressure: <130/70 mm Hg. AD indicates Alzheimer disease; IQR, interquartile
range; no., number.
*n=219 placebo, n=220 nilvadipine (consented to Nilvad frailty-substudy).
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Relationship Between Characteristics and OH
None of the investigated baseline patient characteristics were
signiﬁcant predictors of OH or moderated the effect of
treatment on OH (Table S5). For example, there were no
differences between patients with high, normal, or low BP at
baseline, or between patients with higher or lower frailty
index at baseline. Other baseline characteristics that were
investigated included age, Mini-Mental State Examination
score, diabetes mellitus, use of antihypertensives parallel to
the intervention, use of antidepressants, and use of cholines-
terase inhibitors.
Discussion
These secondary analyses of a randomized clinical trial
investigated the effect of the antihypertensive agent nilvadip-
ine on OH prevalence in patients with mild-to-moderate AD. In
477 patients, of whom 53% had grade I hypertension, a 78-
week intervention with 8 mg of nilvadipine ( other antihy-
pertensives) did not result in a signiﬁcant increase of OH
prevalence, determined with intermittent BP measurements
while sitting and after 1 minute of standing. Moreover, the
number of reported events of fractures, falls, syncope, and
dizziness were similar between the groups. None of the
Figure 2. Effect of treatment on mean sitting SBP and DBP. Mean sitting SBP (A) and DBP (B) per visit and the
number of patients included per visit. After 13 weeks of treatment, sitting SBP and DBP had fallen by 7.814.0
and 3.98.7 mm Hg for nilvadipine and by 0.414.1 and 0.89.1 mm Hg for placebo (P<0.001 for SBP and
DBP). Error bars indicate SEM. DBP indicates diastolic blood pressure; No., number; SBP, systolic blood pressure.
DOI: 10.1161/JAHA.119.011938 Journal of the American Heart Association 6
Orthostatic Hypotension in Alzheimer Disease de Heus et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on July 1, 2019
predeﬁned baseline characteristics moderated the relation-
ship between nilvadipine and OH, indicating that there were
no relevant subgroups for which the results might be
different. These characteristics included age, frailty, or the
use of other medications that could contribute to OH, such as
antidepressants or cholinesterase inhibitors. Previous studies
indicated an immediate effect of starting or intensifying
antihypertensive treatment on falls and fractures in older
people.34,35 We did not see any short-term effects of our
intervention after 6 weeks of treatment (Figure 3). Although
not statistically signiﬁcant, the upper limits of the CIs of our
ﬁndings do not completely rule out a small effect of
nilvadipine. However, as can be seen in Figures 3 and 4,
the magnitude of such an effect would still not lie within
clinically relevant margins.
The antihypertensive properties of nilvadipine are compa-
rable to other, more common dihydropyridine calcium-channel
blockers, such as nifedipine and amlopdipine.21,22 Apart from
that, it is known that the main determinant in reducing
cardiovascular risk is the amount of BP reduction achieved
and not the class of antihypertensive drug.4,36,37 The BP
reduction achieved in our study was moderate, but still falls
within the range of BP reductions observed with other
antihypertensives that successfully reduced cardiovascular
events and mortality.38
It can be questioned whether the absence of a drug class
effect in reducing cardiovascular risk is also applicable to the
risk of OH. For b-blockers, treatment has been associated with
an increased risk of OH,39,40 which might be explained by their
sympatholytic effects interfering with baroreﬂex-mediated BP
recovery.14,15,40 However, the efﬁcacy and safety proﬁle of b-
blockers as ﬁrst-line treatment of hypertension (in older
patients) has already been questioned for other reasons.4,41
For the remaining drug classes, a cross-sectional analysis from
the TILDA (The Irish Longitudinal Study on Ageing) study found
no differences in OH risk between single therapy with calcium-
channel blockers, renin-angiotensin-aldosterone-system block-
ers, and diuretics, arguing against a drug class effect other than
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Figure 3. Effect of treatment on proportion of patients with orthostatic hypotension. Classic orthostatic hypotension (A): drop of ≥20 mm Hg
in systolic BP or ≥10 mm Hg in diastolic BP after 1 minute (OR [95% CI] =1.1 [0.8–1.5], P=0.62). Sit-to-stand orthostatic hypotension (B): of
≥15 mm Hg in systolic BP or ≥7 mm Hg in diastolic BP after 1 minute (OR [95% CI] =1.2 [0.9–1.5], P=0.15). Symptomatic orthostatic
hypotension (C): presence of symptoms upon standing, irrespective of drop in BP (OR [95% CI]=0.8 [0.3–2.3], P=0.67). Delayed orthostatic
hypotension (D): presence of classic orthostatic hypotension after 5 minutes of standing (OR [95% CI]=1.2 [0.9–1.6], P=0.15). No. indicates
number; OR, odds ratio.
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b-blockers and thus favoring the extrapolation of nilvadipine to
antihypertensive treatment in general.40,42
The hypothesis for a link between antihypertensive treat-
ment and OH in older people has mainly emanated from
ﬁndings of observational studies.13 Evidence from randomized
clinical trials is limited, especially in populations with
cognitive impairment.2 The ACCORD (Action to Control
Cardiovascular Risk in Diabetes) trial (Type II diabetes
mellitus, aged 627 years) and AASK (the African American
Study of Kidney Disease and Hypertension) (black patients
with kidney disease and hypertension, aged 5410 years)
trial found no effect of antihypertensive treatment on OH.43,44
Subgroup analyses from SPRINT in people aged ≥75 years
showed no difference in prevalence of OH, falls, or syncope
between the intensive BP-lowering group and the standard
treatment group.17 Also HYVET (the Hypertension in the Very
Elderly Trial) (aged ≥80 years) did not report a difference
between the intervention (indapamide  perindopril) and
placebo group in sitting minus standing BP.18 However, it has
previously been recognized that participants of both SPRINT
and HYVET were relatively ﬁt and healthy and had no cognitive
impairment or dementia,3,45 hampering the extrapolation of
their results to a more frail population. This is an important
limitation, because frailty can decrease the ability to
adequately respond to challenges (ie, antihypertensive treat-
ment) and increase the risks of corresponding adverse
outcomes (ie, OH).28
A slightly more vulnerable population was studied in the
DANTE (Discontinuation of Antihypertensive Treatment in
Elderly People) trial, which assessed the effect of depre-
scribing antihypertensive treatment in people aged
≥75 years with mild cognitive impairment.46 Subgroup
analyses found no convincing evidence that the prevalence
of OH was reduced when antihypertensive medication was
stopped and SBP increased by 4.3 mm Hg.47 Our study
results are in line with SPRINT, HYVET, and DANTE, but now
in a population with mild-to-moderate AD, a group that has
been excluded from previous trials. Although we recognize
that cognitive impairment is just one, albeit a very dominant
one, dimension of frailty,28 this study contributes to
understanding the effect of antihypertensive treatment on
OH in a vulnerable population.
It has been suggested that OH in AD may be related to
autonomic dysfunction instead of cardiovascular disease.48
However, evidence for this is limited, and may have been
biased by misclassiﬁcation of Lewy body dementia as AD.49
We recently demonstrated that baroreﬂex sensitivity was not
impaired in mild-to-moderate AD, which would also argue
against autonomic impairment in AD.50
Strengths and Limitations
Strengths of this study are the thorough design, standardized
procedures, 100% monitoring, and low attrition rate, adding to
Figure 4. Effect of treatment on standing minus sitting BP. The ﬁgure displays DSBP (standing-sitting
SBP) and DDBP (standing-sitting DBP) for nilvadipine and placebo at all visits. As can be seen in the ﬁgure,
the mean DSBP is negative, indicating that standing SBP was lower than sitting SBP. The mean DDBP is
positive, indicating that standing DBP was higher than sitting DBP. BP indicates blood pressure; DBP,
diastolic blood pressure; No., number; SBP, systolic blood pressure.
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a high internal validity. Although these secondary analyses
were not prespeciﬁed in the trial protocol, careful monitoring
of BP, OH, and OH-related outcomes was a preplanned part of
the study for safety reasons. Like any clinical trial, we are
limited by the inclusion and exclusion criteria. This, for
example, resulted in a relatively younger sample of AD
patients compared with the general AD population, where
>80% is older than 75 years. However, certain generalizability
of our ﬁndings is still supported by the heterogeneity of
baseline cognitive scores, frailty levels, age, and the fact that
recruitment took place at both academic and general hospitals.
Extrapolation to clinical AD populations is also aided by the fact
that no biomarker evidence for AD (such as cerebrospinal ﬂuid
or positron emission tomography–amyloid imaging) was
required, as such a requirement may lead to considerable
selection bias (towards younger, less frail AD patients, and
patients seen at tertiary centers). According to the recent
Research Framework for AD of the National Institute on Aging
and the Alzheimer’s Association, our study population would be
classiﬁed as “Alzheimer clinical syndrome.”51
Patients were allowed to use concomitant medication
(provided that it did not interfere with nilvadipine), including
cholinesterase inhibitors and/or memantine and antidepres-
sants. This enhances generalizability, because concomitant
use of these drugs (for example, antidepressants) is not only
common but also increases the risk of falls or OH.52,53
Baseline hypertension was not a requirement for inclusion,
resulting in a study population that does not consist merely of
patients who would normally qualify for antihypertensive
treatment. However, sensitivity analyses showed the same
result in those with baseline hypertension. Moreover, the
absence of adverse effects at lower entry BP levels only
strengthens our ﬁndings and attunes with the latest hyper-
tension guidelines.4
External validity is limited by the exclusion of patients with
severe hypertension (≥160/99 mm Hg). Also, baseline preva-
lence of OH was lower (8%) than previously reported in AD,9
which might be an illustration of inclusion bias toward
healthier patients. This is, however, not supported by the
distribution of the cognitive scores and frailty.
We measured BP using intermittent BP measurements
with patients sitting and 1 minute after they were standing.
Although this deviates from the 3-minute guideline recom-
mendation,54 it was recently suggested that measuring after
1 minute correlates better with clinical outcomes.55 Our
choice to measure BP while patients were sitting rather than
supine may have underestimated the prevalence of OH,
because of reduced gravitational venous pooling. However,
using the proposed diagnostic cut-off for sit-to-stand OH
measurements resulted in similar ﬁndings.32 Finally, the
reliability of reporting adverse event and symptoms upon
standing might be low in a population with cognitive
impairment, possibly leading to underreporting. These con-
cerns were in part mitigated, however, because we con-
ducted regular semistructured interviews with the patient’s
caregiver.
Perspectives
The implications of our ﬁndings are 2-fold. First, our study
adds to the discussion on the beneﬁt-to-risk ratio of the use of
antihypertensive medication in AD,56 by providing hitherto
missing evidence that OH risk is not exacerbated by
treatment. Although more evidence is required, some patients
with mild-to-moderate AD may still beneﬁt from antihyper-
tensive treatment. For instance, the average estimated
survival after AD diagnosis is 3 to 9 years,57 while positive
effects of antihypertensive treatment in the elderly already
become apparent after 1 year of treatment.17,18 Furthermore,
comorbidities, including cardiovascular and cerebrovascular
events, can have detrimental effects on progression of AD,
and are 1 of the major causes of death in AD.58–60 Thus,
withholding treatment in a patient with AD because of an
overestimated fear of OH might negatively affect patient
Figure 5. Effect of treatment on proportion of reported clinical outcomes related to orthostatic hypotension. Odds ratio results from logistics
regression. No. indicates number; OR, odds ratio.
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outcomes. Instead, we advocate that decisions regarding
antihypertensive treatment should always be tailored to
patient’s preferences and physical and mental status.56
Another implication of our ﬁndings is that they add to the
complex debate on the use of antihypertensive medication in
vulnerable older people,6 of which this AD population is an
important example. It is a persistent belief among many
physicians that treating older people with antihypertensive
medication would do more harm than good.7 The current
study has recruited, to date, the most vulnerable population
and found that treatment with a low-dose calcium-channel
blocker led to an effective, moderate BP reduction without
causing harm in the sense of OH, or OH-related adverse
outcomes such as falls or fractures.
Conclusions
In patients with mild-to-moderate AD, with or without
hypertension, 78-week treatment with 8 mg of the calcium-
channel blocker nilvadipine did not signiﬁcantly increase the
risk of OH, fractures, falls, syncope, and dizziness. We provide
evidence that starting or adding a low dose of antihyperten-
sive treatment is safe with respect to OH and clinical
outcomes. Trials that are primarily designed to investigate
patient-relevant beneﬁcial as well as adverse outcomes of
antihypertensive treatment are required to elicit the full
beneﬁt-to-risk balance in this quickly growing patient group.
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Table S1. Composition of the Frailty Index. 
# Item Response Sc
ore 
Notes 
1 Gait speed ≥ 0.67 m/s 0 
< 0.67 m/s 1 
2 Use of a walking aid when 
performing gait speed test 
No 0 
Yes 1 
3 Polypharmacy, based on trial 
record of concomitant medication 
≤5 0 
6 0.2 
7 0.4 
8 0.6 
9 0.8 
≥10 1 
4 Body Mass Index 18.5 – 29.9 0 
<18.5 1 
≥ 30 1 
5 3 items from ADAS-cog combined: 
- Spoken language ability
- Comprehension
- Word finding in spontaneous
speech
No difficulty 0 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
Very mild difficulty 0.2 
Mild difficulty 0.4 
Moderate difficulty 0.6 
Moderate-severe 
difficulty 
0.8 
Severe difficulty 1.0 
6 2 items from CDR combined: 
- Memory
- Orientation
No problem 0 Take the sum of the 
original items, 
categorize to: ≤1.0= 
0; 1.5= 0.17; 2.0= 
0.33; 2.5= 0.50; 
3.0= 0.67; 3.5= 
0.83; ≥4.0= 1 
Probably a problem 0.5 
Mild problem 1 
Moderate problem 2 
Severe problem 3 
7 3 items about contact with family 
from the LSNS combined: 
- Number of relatives seen or called
once a month
- Number of relatives to call for
help
- Number of relatives to talk about
private things
None 1 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
1 person 0.8 
2 persons 0.6 
3-4 persons 0.4 
5-9 persons 0.2 
>9 persons 0 
8 3 items about contact with friends 
from the LSNS combined: 
- Number of friends seen or called
once a month
- Number of friends to call for help
- Number of friends to talk about
private things
None 1 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
1 person 0.8 
2 persons 0.6 
3-4 persons 0.4 
5-9 persons 0.2 
>9 persons 0 
9 3 items about taking a bath or 
shower combined: 
- Undertake a bath or a shower
Able without help 0 Take the sum of the 
original items / 
number of filled 
Not able without 
help 
1 
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- Prepare utilities needed to take a
bath or shower
- Wash and dry body parts
completely and safely
items (0 = no deficit, 
1=full deficit) 
10 2 items about taking care of hair: 
- Decide to care hair
- Caring hair
Able without help 0 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
Not able without 
help 
1 
11 5 items about getting dressed 
completely and appropriately: 
- Undertake to dress
- Choose appropriate clothing
- Dress in appropriate order
- Dress completely
- Undress completely
Able without help 0 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
Not able without 
help 
1 
12 2 items about eating: 
- Choose appropriate seasoning and
utensils
- Eat appropriately
Able without help 0 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
Not able without 
help 
1 
13 3 items about preparing a light 
meal: 
- Undertake to prepare a light meal
- Plan a light meal
- Cook a light meal safely
Able without help 0 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
Not able without 
help 
1 
14 3 items about using the telephone: 
- Attempt to telephone at a suitable
time
- Dial a telephone correctly
- Conduct telephone conversation
appropriately
Able without help 0 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
Not able without 
help 
1 
15 4 items about travelling or doing an 
outing: 
- Undertake to go out at appropriate
time
- Adequaltely organize an outgoing
- Go out and reach destination
without getting lost
- Safely take adequate mode of
transportation
Able without help 0 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
Not able without 
help 
1 
16 3 items about managing finances: 
- Show interest in personal finance
- Organise peronsal finance
- Handle money correctly
Able without help 0 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
Not able without 
help 
1 
17 2 items about taking medication: 
- Decide to take medication at
correct time
- Take medication as prescribed
Able without help 0 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
Not able without 
help 
1 
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1=full deficit) 
18 3 items about performing 
household tasks: 
- Show interest in performing
household
- Plan to perform household
- Perform household correctly
Able without help 0 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
Not able without 
help 
1 
19 2 items for urinary incontinence: 
- Decide to use the toilet
appropriately
- Use toilet without accidents
Able without help 0 Take the sum of the 
original items / 
number of filled 
items (0 = no deficit, 
1=full deficit) 
Not able without 
help 
1 
20 History of cerebrovascular disease None 0 
Present 1 
21 History of chronice pulmonary 
disease 
None 0 
Present 1 
22 History of congestive heart failure None 0 
Present 1 
23 History of cancer None 0 
Present 1 
24 History of cardiovascular disease None 0 
Present 1 
25 History of renal disease None 0 
Present 1 
26 History of diabetes None 0 
Without end organ 
damage 
0.5 
With end organ 
damage 
1 
Measurement instrument for items 9 t/m 19 was DAD questionnaire. Measurement instrument 
for items 20 t/m 26 was Charlson’s Comorbidity Index. ADAS-cog= Alzheimer’s disease 
Assessment Scale - cognitive subscale; CDR= Clinical Dementia Rating; LSNS= Lubben 
Social Network Scale; DAD= Disability Assessment for Dementia questionnaire. 
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Table S2. Patient demographics and characteristics for complete cases. 
Characteristic Placebo Nilvadipine 
n 167 164 
Women,  No. (%) 91 (54.5) 114 (69.5) 
Age, mean (SD), y 71.0 (7.5) 71.0 (8.5) 
Time since diagnosis of AD, median (IQR), y 0.8 (0.3-2.1) 1.2 (0.5-2.1) 
Mini-Mental State Examination score, mean (SD) 20.7 (3.8) 20.3 (3.6) 
AD Assessment Scale-cognitive subscale, mean (SD) 34.7 (10.7) 33.9 (10.0) 
Clinical Dementia Rating-sum of boxes, mean (SD) 5.1 (2.7) 5.1 (2.7) 
Frailty index
*
 median (IQR) 0.16 (0.1-0.3) 0.17 (0.1-0.2) 
Sitting systolic blood pressure, mean (SD), mmHg 137.0 (14.3) 138.0 (13.0) 
Sitting diastolic blood pressure, mean (SD), mmHg 77.4 (8.5) 76.9 (8.4) 
Resting hear rate, mean (SD), beats per min 69.2 (9.6) 70.1 (10.5) 
Classic orthostatic hypotension, No. (%) 16 (9.6) 9 (5.5) 
Sit-to-stand orthostatic hypotension, No. (%) 24 (14.4) 25 (15.2) 
Symptomatic orthostatic hypotension, No. (%) 3 (1.8) 7 (4.3) 
Delayed orthostatic hypotension, No. (%) 15 (9.0) 9 (5.5) 
Δ systolic blood pressure, mean (SD), mmHg -1.02 (9.46) -1.70 (10.39)
Δ systolic blood pressure, mean (SD), % -0.58 (6.86) -1.07 (7.58)
Use of medication at study enrollment, No. (%) 
     At least 1 antihypertensiv medication, No. (%) 62 (37.1) 52 (31.7) 
      Cholinesterase inhibitors, No. (%) 149 (89.2) 145 (88.4) 
     Memantine, No. (%) 47 (28.1) 40 (24.4) 
     Antidepressants, No. (%) 65 (38.9) 58 (35.4) 
     Statins, No. (%) 58 (34.7) 50 (30.5) 
     Antithrombotics, No (%) 48 (28.7) 36 (22.0) 
History of CVD, No. (%) 12 (7.2) 9 (5.5) 
Diabetes, No. (%) 4 (2.4) 16 (9.6) 
*
 n=154 placebo, n=150 nilvadipine (consented to Nilvad frailty-substudy). AD=Alzheimer’s 
disease; CVD=cardiovascular disease. 
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Table S3. In- and exclusions from the per protocol analysis per follow-up visit. 
Placebo (n=237) 
Week No. Included, No. (%) Excluded, No. (%) 
Off IMP Not compliant Missing BP Deceased 
6 231  (97.5) 0 (0.0) 5 (2.1) 1 (0.4) 0 (0.0) 
13 229 (96.6) 2 (0.8) 5 (2.1) 1 (0.4) 0 (0.0) 
26 220 (92.8) 7 (3.0) 8 (3.4) 1 (0.4) 1 (0.4) 
39 212 (89.5) 12 (5.1) 10 (4.2) 1 (0.4) 2 (0.8) 
52 196 (82.7) 25 (10.5) 14 (5.9) 0 (0.0) 2 (0.8) 
65 192 (81.0) 30 (12.7) 12 (5.1) 0 (0.0) 3 (1.3) 
78 190 (80.2) 34 (14.3) 9 (3.8) 1 (0.4) 3 (1.3) 
Nilvadipine (n=240) 
Week No. Included, No. (%) Excluded, No. (%) 
Off IMP Not compliant Missing BP Deceased 
6 234 (97.5) 0 (0.0) 5 (2.1) 1 (0.4) 0 (0.0) 
13 232 (96.7) 2 (0.8) 5 (2.1) 1 (0.4) 0 (0.0) 
26 222 (92.5) 12 (5.0) 5 (2.1) 0 (0.0) 1 (0.4) 
39 203 (84.6) 25 (10.4) 9 (3.8) 2 (0.8) 1 (0.4) 
52 195 (81.3) 37 (15.4) 5 (2.1) 1 (0.4) 2 (0.8) 
65 186 (77.5) 43 (17.9) 7 (2.9) 2 (0.8) 2 (0.8) 
78 179 (74.6) 47 (19.6) 8 (3.3) 4 (1.7) 2 (0.8) 
Not compliant indicates a compliance <80% in the 3-month window preceding the visit (6-
week window for the week 6 visit). IMP= investigational medicinal product; BP=blood 
pressure. 
.
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Table S4. Effect of treatment on orthostatic hypotension. 
Per protocol Complete cases 
Logistic regression models OR [95% CI], P OR [95% CI], P 
Classic OH 1.1 [0.8 - 1.5], 0.62 1.1 [0.8 - 1.6], 0.55 
Sit-to-stand OH 1.2 [0.9 - 1.5], 0.15 1.2 [0.9 - 1.7], 0.13 
Symptomatic OH 0.8 [0.3 - 2.3], 0.67 0.9 [0.2 - 3.4], 0.84 
Delayed OH 1.2 [0.9 - 1.6], 0.15 1.3 [0.9 - 1.8], 0.19 
Independent samples t-test mean diff. [95% CI], P mean diff. [95% CI], P 
Classic OH -0.4 [-2.7 - 1.9], 0.72 -0.8 [-3.3 - 1.7], 0.52
Sit-to-stand OH -2.7 [-5.8 - 0.4], 0.09 -2.6 [-5.8 - 0.7], 0.12
Symptomatic OH 0.7 [-0.6 - 2.0], 0.31 0.1 [-1.3 - 1.4], 0.94
Delayed OH -1.1 [-3.5 - 1.3], 0.36 -1.7 [-4.3 - 0.9], 0.20
Linear regression models β [95% CI], P β [95% CI], P 
ΔSBP, mmHg -0.8 [-1.7 - 0.2], 0.13 -1.1[-2.2 -  0.0], 0.04
ΔSBP, % -0.6 [-1.3 - 0.2], 0.12 -0.9 [-1.7- -0.1], 0.04
Logistic regression models report the odds ratio of treatment after correction for baseline 
ΔSBP and with random intercepts for patient and study centre. Independent samples t-test 
report the mean difference between groups for the proportion of visits during which a patient 
met criteria for OH. Classic OH: drop of ≥20 mmHg in systolic BP or ≥10 mmHg in diastolic 
BP after 1 minute. Sit-to-stand OH: drop of ≥15 mmHg in systolic BP or ≥7 mmHg in 
diastolic BP after 1 minute. Symptomatic OH: presence of symptoms upon standing, 
irrespective of the drop in BP. Delayed OH: presence of classic OH after 5 minutes of 
standing. Linear regression models report bèta of treatment after correction for baseline ΔSBP 
with random intercept for patient and study centre. ΔSBP: change in systolic blood pressure 
from sitting to standing expressed in mmHg and in % from sitting systolic blood pressure. 
OR, oddds ratio; CI, confidence interval; OH, orthostatic hypotension; SBP, systolic blood 
pressure. 
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Table S5. Results from regression models estimating the effect of treatment and 
moderators on orthostatic hypotension.
BP status MMSE score Age Frailty Index 
Parameter β (SE) P β (SE) P β (SE) P β (SE) P 
Classic OH 
   Treatment 0.52 (0.37) 0.16 1.58 (0.91) 0.08 0.07 (0.16) 0.68 -0.05 (0.37) 0.89 
   Moderator 0.04 (0.18) 0.82 0.03 (0.03) 0.37 0.01 (0.02) 0.47 0.98 (1.12) 0.38 
   Interaction -0.30 (0.24) 0.19 -0.07 (0.04) 0.09 0.00 (0.02) 0.87 0.75 (1.52) 0.62 
Sit-stand OH 
   Treatment 0.26 (0.29) 0.38 1.23 (0.71) 0.09 -0.33 (113) 0.77 0.20 (0.13) 0.13 
   Moderator -0.01 (0.14) 0.95 0.03 (0.03) 0.18 0.00 (0.01) 0.97 0.27 (0.92) 0.77 
   Interaction -0.05 (0.19) 0.78 -0.05 (0.03) 0.14 0.01 (0.02) 0.65 1.15 (1.24) 0.36 
ΔSBP (mmHg) 
   Treatment -1.47(1.13) 0.20 -3.47 (2.64) 0.19 -4.67 (4.36) 0.29 -0.74 (0.49) 0.14 
   Moderator 0.28 (0.51) 0.58 -0.04 (0.09) 0.66 -0.02 (0.05) 0.69 -0.67 (3.31) 0.84 
   Interaction 0.49 (0.72) 0.50 0.14 (0.13) 0.29 0.05 (0.06) 0.37 0.99 (4.70) 0.83 
ΔSBP (%) 
   Treatment -1.25 (0.86) 0.15 -2.48 (2.02) 0.22 -3.90 (3.34) 0.24 -0.58 (0.37) 0.12 
   Moderator 0.22 (0.39) 0.57 -0.02 (0.07) 0.73 -0.02 (0.03) 0.63 -0.56 (2.52) 0.82 
   Interaction 0.45 (0.55) 0.41 0.10 (0.10) 0.33 0.05 (0.05) 0.32 1.25 (3.58) 0.73 
Diabetes Additional 
antihypertensive 
Antidepressant Cholinesterase 
inhibitor  
Parameter β (SE) P β (SE) P β (SE) P β (SE) P 
Classic OH 
   Treatment 0.09 (0.16) 0.60 0.11 (0.19) 0.56 0.10 (0.20) 0.60 0.14 (0.43) 0.74 
   Moderator -0.04 (0.65) 0.95 -0.02 (0.24) 0.93 0.11 (0.25) 0.66 -0.34 (0.35) 0.32 
   Interaction -0.05 (0.75) 0.95 -0.12 (0.35) 0.73 -0.07 (0.33) 0.83 -0.08 (0.46) 0.86 
Sit-stand OH 
   Treatment 0.17 (0.13) 0.18 0.07 (0.15) 0.63 0.15 (0.16) 0.35 0.31 (0.37) 0.41 
   Moderator -0.13 (0.53) 0.81 -0.39 (0.20) 0.05 0.23 (0.20) 0.25 -0.01 (0.30) 0.98 
   Interaction 0.17 (0.60) 0.78 0.30 (0.28) 0.27 0.07 (0.26) 0.78 -0.15 (0.40) 0.71 
ΔSBP (mmHg) 
   Treatment -0.90 (0.51) 0.08 -0.98 (0.61) 0.11 -0.67 (0.61) 0.27 -2.36 (1.45) 0.10 
   Moderator 0.17 (1.95) 0.09 0.36 (0.72) 0.62 -0.32 (0.74) 0.67 0.55 (1.13) 0.62 
   Interaction 1.26 (2.24) 0.57 0.71 (1.03) 0.49 -0.21 (1.01) 0.83 1.84 (1.54) 0.23 
ΔSBP (%) 
   Treatment -0.69 (0.39) 0.08 -0.75 (0.47) 0.11 -0.49 (0.47) 0.30 -1.77 (1.11) 0.11 
   Moderator 0.12 (1.50) 0.94 0.32 (0.55) 0.57 -0.26 (0.57) 0.65 0.33 (0.87) 0.70 
   Interaction 0.90 (1.72) 0.60 0.53 (0.79) 0.50 -0.24 (0.78) 0.76 1.37 (1.18) 0.25 
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Results from logistic regression models (classic OH, sit-stand OH) or linear regression models 
(ΔSBP), with random intercepts for patient and study site, fixed effects for treatment, baseline 
ΔSBP and moderator and the interaction term for treatment*moderator. Definitions: classic 
OH=drop of ≥20 mmHg in systolic BP or ≥10 mmHg in diastolic BP after 1 minute. Sit-stand 
OH=drop of ≥15 mmHg in systolic BP or ≥7 mmHg in diastolic BP after 1 minute. 
ΔSBP=change in systolic blood pressure from sitting to standing expressed in mmHg and in 
% from sitting systolic blood pressure. BP status=high (≥140/90 mmHg), normal (130-
139/70-89 mmHg) or low (<130/70 mmHg) blood pressure at baseline.  
OH, orthostatic hypotension; SBP, systolic blood pressure; MMSE, Mini-Mental State 
Examination; AHD, antihypertensive drug; ΔSBP, change in systolic BP from sitting to 
standing.
D
ow
nloaded from
 http://ahajournals.org by on July 1, 2019
Mean sitting systolic (A, B, C) and diastolic (E, F, G) blood pressure per visit in patients 
with high (≥140/90 mmHg), normal (130-139/70-89 mmHg) and low (<130/70 mmHg) 
baseline blood pressure for nilvadipine (dashed line) and placebo (solid line). After 13 weeks 
of treatment, mean difference between nilvadipine and placebo was -8.0/-3.5 mmHg, 
-4.7/-1.7 mmHg and -7.6/-3.5 mmHg for high-, normal- and low-BP, respectively. No 
interaction was present between treatment and baseline BP (P=0.45 for systolic and P=0.55 
for diastolic blood pressure), assessed after 13 weeks. Error bars indicate standard error of 
mean. 
BP=blood pressure. 
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No . o f pa tien ts  
  Place bo  1 18  11 5 1 13  1 12  10 6  98  96  9 4  
  Nilvadipin e  1 37  13 2 1 30  1 26  11 4  11 1  10 6 1 0 0 
No . o f pa tien ts  
  Place bo  9 3  90  9 0 8 4 82  75  73  7 3  
  Nilvadipin e  7 6  75  7 5 7 1 68  64  62  6 2  
No. o f pa tien ts  
  Placebo  26  26  26 24 24  23  23  23  
  N ilvadipine  27  27  27 25 21  20  18  17  
High baseline BP (140/90 mmHg) Normal baseline BP (130-139/70-89 mmHg) Low  baseline BP (<130/70 mmHg)
Figure S1. Effect of treatment on sitting systolic and diastolic blood pressure in patients with high, normal and low blood pressure at baseline 
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Mean sitting systolic (A, B, C) and diastolic (E, F, G) blood pressure per visit in the 
complete cases (A, D) and in non-users (B, D) and users (C, F) of additional antihypertensive 
drugs parallel to the intervention for nilvadipine (dashed line) and placebo (solid line). After 
13 weeks of treatment, mean difference between nilvadipine and placebo was -7.4/-3.1 
mmHg, -8.0/-3.9 mmHg, -6.1/-1.7 mmHg for complete cases, non-users and users, 
respectively. No interaction was present between treatment and use of antihypertensive drugs 
(P=0.48 for systolic and P=0.20 for diastolic blood pressure). Error bars indicate standard 
error of mean. BP=blood pressure; AHD=antihypertensive drugs. 
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Complete cases No aditional AHD users Additional AHD users
No. of patients  
  Placebo  167  167 167  167  167  167  167 167 
  Nilvadipine  164  164 164  164  164  164  164 164 
No . o f pa tien ts  
  Placebo  137  133 132  128  123  11 2  11 1 1 0 7 
  Nilvadipin e  156  152 151  142  133  12 6  12 3 1 1 7 
No . o f pa tien ts  
  Placebo  9 7  98  9 7 9 2 89  84  81  8 3  
  Nilvadipine  8 1  82  8 1 8 0 70  69  63  6 2  
Figure S2. Effect of treatment on sitting systolic and diastolic blood pressure for complete cases and for use of additional antihypertensive drugs parallel to the intervention.
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